SEC Form 4 · accession 0000899243-16-017488
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patricia L Allen
Officer — Chief Financial Officer
Period of report
Mar 31, 2016
Accepted (ET)
Apr 4, 2016 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.68 | Mar 31, 2016 | A | 72,000 | A | — | Mar 31, 2026 | Common Stock | 72,000 | 72,000 | D |
| Stock Option (Right to Buy)F2 | $6.68 | Mar 31, 2016 | A | 36,000 | A | — | Mar 31, 2026 | Common Stock | 36,000 | 36,000 | D |
Explanation of responses
- F125% of this option vests on March 31, 2017, and the remainder vests in equal monthly installments thereafter over 36 months.
- F2This option vests as follows: 25% on March 31, 2017; 25% on September 30, 2017; and 50% on March 31, 2018.